3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Burkitt Lymphoma
2
Spondylarthritis
1
Rectal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Arthritis, Rheumatoid
1
Interventions
Adalimumab
13
Methotrexate
11
Etanercept
10
Rituximab
5
Abatacept
5
tocilizumab
4
olokizumab
4
tofacitinib
3
golimumab
3
Infliximab
3
Tumor Necrosis Factor Inhibitors
2
Saline Solution
2
RC-18
2
Nivolumab
2
Leflunomide
2
Certolizumab Pegol
2
Antirheumatic Agents
2
veltuzumab
1
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
entecavir
1
cabozantinib
1
baricitinib
1
andecaliximab
1
Vitamin D
1
Vaccines
1
TACI receptor-IgG Fc fragment fusion protein
1
Syringes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Arthritis, Rheumatoid
×
Radioimmunodetection
×
Clear all
NCT01590966
2019-08-26
SCINTRA
University Hospital, Ghent
Phase 3
Completed
41 enrolled